AzTrials
AzTrials

MalariaNCT04241705

Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia

A study testing Treatment of positive individuals per national treatment guidelines and Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) in people with Malaria, run by Armauer Hansen Research Institute, Ethiopia at 10 sites in Ethiopia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Reactive and proactive case detection measures are widely implemented by national malaria elimination programs globally. Similarly, the Ethiopian Federal Ministry of Health decided to include reactive case detection (RCD) and targeted mass drug administration (tMDA) approaches as part of their elimination strategy… Read more about this study

Who is it for?
Ages 6 months and older
Conditions the study is for
Malaria
What is being tested?
Treatment of positive individuals per national treatment guidelines and Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48,960 participants
Where
10 sitesEthiopia
Study dates
20 Jan 2020to 20 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Woreda-level: Of the 19 woredas with malaria risk, the ten woredas with the highest annual parasite incidence (API) in 2018 will be eligible for the study.
  • For Kebeles:
  • Kebeles in East Hararghe Zone targeted for implementation of elimination activities by the Ethiopian Federal Ministry of Health where there is ongoing PMI-supported malaria surveillance;
  • Kebeles with reported API between 1 and 50;
  • Kebeles in malarious districts with comparable optimization of malaria control interventions.
  • For individual participants:
  • All residents of the intervention study kebeles diagnosed with malaria at health facilities (index case) or reside within 100-meter radius with the index case and has NONE of the exclusion criteria listed below
  • Able to provide informed written consent

Who cannot join

  • For kebeles: Kebeles planning on starting for the first time or discontinuing indoor residual spraying (IRS) campaigns in the next two years.
  • For individual participants:
  • Children less than 6 months of age or <5 kg
  • Known allergy or history of adverse reaction or chronic/congenital disease contra indicated to any of the intervention drugs: PQ, AL or CQ
  • Individuals with severe malnutrition or signs of severe disease, with evidence of any organ failure or Hgb level < 8gm/dl
  • Household members already covered by the intervention less or equal to one month before
Show all 10Show fewer
  • In addition, the following individuals will be excluded from receiving primaquine:
  • Phenotypically G6PD deficient individuals
  • Pregnant women
  • Lactating women breastfeeding infants less than 6 months of age or with unknown G6PD status

Trial locations and contacts

10 sites in 1 country.

Endalamaw Gadisa, PhD, MSc contact

+251911868827

endalamaw.gadisa@ahri.gov.et

Ayele Zewdie, MD, MPH contact

+251911764018

ayelezewdew@gmail.com

10 sites in 1 country

Ethiopia10 sites, 10 recruiting

  • Woreda 6:

    ‘Alemaya

    Recruiting

  • Woreda 1:

    Babīlē

    Recruiting

  • Woreda 2:

    Fedīs

    Recruiting

  • Woreda 3:

    Girawa

    Recruiting

  • Woreda 4:

    Golo Oda

    Recruiting

  • Woreda 5:

    Gursum

    Recruiting

  • Woreda 7:

    Kersa

    Recruiting

  • Woreda 8:

    Kombolcha

    Recruiting

  • Woreda 9:

    Kurfa Chele

    Recruiting

  • Woreda 10:

    Midega Tola

    Recruiting

Other trials in Ethiopia

About this study

Official title: Evaluation of the Effect of Targeted Mass Drug Administration and Reactive Case Detection on Malaria Transmission and Elimination in East Hararghe Zone, Oromia, Ethiopia

Reactive and proactive case detection measures are widely implemented by national malaria elimination programs globally. Similarly, the Ethiopian Federal Ministry of Health decided to include reactive case detection (RCD) and targeted mass drug administration (tMDA) approaches as part of their elimination strategy, along with rigorous evaluation. This study aims to evaluate the impact on annual parasite incidence (API) and cost-effectiveness of implementing tMDA and RCD within a 100-meter radius of passively detected index case, compared with standard of care in the control arm. In addition, cross-sectional surveys will measure the change in malaria prevalence over the two-year study intervention period. The aim is to generate evidence to inform Ethiopia's national strategy for malaria elimination.

Read the detailed description

Study design: Cluster randomized controlled trial

Primary aim: To compare the effect of targeted mass drug administration (tMDA) versus reactive case detection (RCD) on reducing malaria incidence

Study site: Elimination targeted areas within East Hararghe Zones, Oromia Regional State, which is comprised of 24 woredas/districts

Cluster or unit of randomization: Kebeles will be randomized to the control, RCD or tMDA arms using simple randomization

Evaluation methods: The primary outcome measure of annual parasite incidence (API) will be obtained through routine surveillance data at all health facilities (health centers and health posts).

Secondary outcomes will be measured through cross-sectional surveys and study monitoring data:

  1. Case investigation. At the time of diagnosis of the index case and enrollment of community members to the study, a short questionnaire will be administered to collect demographic data and assess malaria risk, including past malaria treatment and travel history, access to malaria interventions, occupation, etc.
  2. Cross-sectional surveys. At baseline and end of the study period (year 2), cross-sectional household surveys will be conducted to assess malaria prevalence, household and individual risk factors for malaria, including access to malaria interventions. It will also assess knowledge of, attitude towards, and participation in the study intervention.
  3. Longitudinal feasibility measurements: Coverage of RCD or tMDA in the target population, acceptability of RCD or tMDA in the target population, serious adverse event (SAE) reports, adherence measured by self-report and pill count, and cost data from all arms
  4. Laboratory testing: The conventional rapid diagnostic test (RDT) for malaria will be used in the RCD arm. Dried blood spots (DBS) will be collected for molecular and serological testing during the cross-sectional surveys in all arms. DBS collected in incident cases as part of routine surveillance as well as during the RCD activities will also be utilized for antigen, antibody, and molecular testing. G6PD testing will be used in the RCD and tMDA arm to guide primaquine (PQ) treatment.

Sample size: To measure the primary outcome, change in incidence, 16,000 Households (HH) (16 clusters, 1,000 HH each) per arm will be included in the study. For the cross-sectional surveys, 320 randomly selected HHs per arm (16 clusters, 20HH/cluster) will be included.

Conditions
Malaria
Being tested
Treatment of positive individuals per national treatment guidelines, Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ), Optimized malaria control interventions
Keywords
Targeted mass drug administration, Reactive case detection
Medical subject headings
Malaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Treatment of positive individuals per national treatment guidelinesOther

    Treatment for everyone except children <6 months of age, pregnant women, women breastfeeding children <6 months of age, and women 12-49 years of age with an unknown pregnancy status:

    • P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)
    • P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)
    • Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)

    Treatment for pregnant women and women breastfeeding children <6 months of age:

    • P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)
    • P. vivax cases: Chloroquine (CQ)

  • Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)Other

    Everyone who is eligible for the study except pregnant women and women breastfeeding children <6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.

    • Women in the first trimester of pregnancy will be treated presumptively with quinine.
    • Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).

    Again, treatment will be given without RDT for malaria.

  • Optimized malaria control interventionsOther

    Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.

Study groups in NCT04241705
Study groupRoleWhat they receive
Control armActive comparatorThe control arm will provide optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services.
Receives: Other: Optimized malaria control interventions
Reactive Case Detection (RCD) armActive comparatorOptimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive, passively-detected index cases at the health post or health center; individuals who reside within a 100-meter radius of the index case will receive diagnosis for malaria using a conventional RDT. Positive individuals will receive treatment and follow-up as per the national treatment guidelines. 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing. Additional procedures will include the collection of a dried blood spot.
Receives: Other: Treatment of positive individuals per national treatment guidelines; Other: Optimized malaria control interventions
Targeted Mass Drug Administration (tMDA) armExperimentalOptimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive index cases at the health post or health center, all eligible individuals who reside within a 100-meter radius of the index case will receive presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) (0.25mg/kg daily). 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing.
Receives: Other: Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ); Other: Optimized malaria control interventions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in malaria annual parasite incidence (API)

    The effect of RCD or tMDA will be defined as a change in malaria API among residents measured by microscopy/RDT through health centers and health posts. The malaria API will be defined as all passively detected RDT or microscopy confirmed cases over a period of 12 months, who are residents of the kebele divided by the estimated population in the intervention kebele multiplied by 1000. The primary effectiveness endpoint will therefore be API among residents of the kebele at baseline and year 2 of each intervention group of study clusters, compared with the control clusters.

    Measured: Two years

Secondary outcomes (11)

  1. Malaria burden, measured by antigen test

    Testing for pan-Plasmodium antigens aldolase and LDH will determine active infection with malaria parasite, and, if the infecting species is Pf, by the presence of HRP2 antigen (Plucinski, Herman et al. 2018).

    Measured: Two years

  2. Malaria burden, measured by serology

    Sero-prevalence will be determined using LUMINEX based multiplex assays. Age-specific sero-conversion and sero-reversion rates over the two years will be used to monitor changes in transmission and malaria exposure over time. Absence of antimalarial antibodies, particularly in children, will show the success of tMDA or RCD interventions. Antigen selection will be informed by recent studies by EPHI and CDC and a panel of antibodies characterized to indicate recent change in transmission will be included (Kerkhof, Sluydts et al. 2016).

    Measured: Two years

  3. Malaria burden, measured by molecular testing

    Real-time quantitative (qPCR) for parasite detection will be performed by targeting the 18S small rRNA gene for Pf and Pv using primer and probe sequences. Pf parasites will be quantified using standard curves generated from a serial dilution of NF54 ring stage parasites. Pv parasite quantification will be done using plasmid constructs to infer copy numbers as described before. Blood samples in RNA protect buffers will be used for extraction of RNA using the RNeasy Mini Kit (QIAGEN) for gametocyte quantification, gametocyte commitment and maturation assays, sex ratio estimation, asexual stage parasites detection, and expression level of regulators of the balance between reproduction and replication.

    Measured: Two years

  4. Intervention coverage

    To compare intervention coverage in RCD and tMDA arms. After RCD and tMDA interventions, coverage will be estimated by calculating the proportion of all enumerated household members reached in each index case event and the proportion of individuals tested and/or on treatment.

    Measured: Two years

  5. Acceptability

    To compare acceptability of RCD and tMDA. During the baseline and endline cross-sectional surveys, the household head will be asked questions about the acceptability of the RCD and tMDA interventions (self-report).

    Measured: Two years

  6. Serious adverse events

    To compare number of serious adverse events between the RCD and tMDA arms

    Measured: Two years

  7. Adherence

    To compare the adherence to antimalarials between the RCD and tMDA arms. Adherence will be measured by self-report and pill count.

    Measured: Two years

  8. Costs

    To compare the costs of RCD and tMDA. Costs will be calculated using an ingredients approach that involves enumerating both the quantity of specific inputs (e.g., hours spent, cost of treatment, number of RDTs used, etc.) and the time spent during the intervention. Quantity and time will be converted to a common monetary cost measure. Existing infrastructure and recurrent inputs that would be present in the absence of the intervention will not be included in cost analysis. The emphasis of the cost analysis is on determining the cost of RCD and tMDA alone.

    Measured: Two years

  9. Cost-effectiveness

    To assess the cost-effectiveness of RCD and tMDA relative to control. Cost-effectiveness will be measured through incident malaria cases averted as measured through the difference in malaria incidence in RCD and tMDA kebeles.

    Measured: Two years

  10. Sensitivity and specificity of polymerase chain reaction (PCR)

    To evaluate the sensitivity and specificity of PCR as compared to antigen- based multiplex testing

    Measured: Two years

  11. Ratio of imported to locally acquired incident cases

    To assess the ratio of imported to locally acquired incident cases

    Measured: Two years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2020
  2. Study start20 Jan 2020
  3. Primary completion20 Jan 2022 (estimated)
  4. Study completion20 Jan 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
48,960 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04241705
Sponsor's protocol ID
1
Status last verified
Jun 2020
First submitted
2 Jan 2020
Last updated
12 Jun 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Abdelmenan S, Teka H, Hwang J, Girma S, Chibsa S, Tongren E, Murphy M, Haile M, Dillu D, Kassim J, Behaksra S, Tadesse FG, Yukich J, Berhane Y, Worku A, Keating J, Zewde A, Gadisa E. Evaluation of the effect of targeted Mass Drug Administration and Reactive Case Detection on malaria transmission and elimination in Eastern Hararghe zone, Oromia, Ethiopia: a cluster randomized control trial. Trials. 2022 Apr 7;23(1):267. doi: 10.1186/s13063-022-06199-8.

    PubMed 35392979

Questions about this trial

What is this clinical trial studying?

A study testing Treatment of positive individuals per national treatment guidelines and Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) in people with Malaria, run by Armauer Hansen Research Institute, Ethiopia at 10 sites in Ethiopia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Endalamaw Gadisa, PhD, MSc (+251911868827, endalamaw.gadisa@ahri.gov.et), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in malaria annual parasite incidence (API) (time frame: Two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04241705, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in